Asian study shows ADHD disability burden peaks in early adolescence

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder and imposes a lifelong burden extending beyond core symptoms to academic achievement, quality of life, and long-term disability. Its economic and functional costs are substantial, yet comparable evidence on ADHD-related disability across Asia remains limited because earlier studies often focused on single countries, restricted age groups, or selected regions. Healthcare access, diagnostic practices, educational environments, and public awareness vary widely across Asia, complicating regional and national comparisons. The COVID-19 pandemic further disrupted schooling, routines, and service access, adding uncertainty about whether observed changes reflect true burden or shifts in recognition and reporting. A comprehensive assessment is therefore needed to inform targeted prevention, early identification, and management strategies across Asia.

Published (DOI: 10.1007/s12519-026-01091-w) online on October 9, 2026, in World Journal of Pediatrics, the study was conducted by leading researchers from Kyung Hee University College of Medicine in Seoul, South Korea, with collaborators at other institutions. Using the Global Burden of Disease Study 2023 (GBD 2023), the team examined ADHD related years lived with disability (YLDs) across 34 Asian countries from 1990 to 2023, comparing patterns by age, sex, region, socioeconomic development, and pandemic period.

To capture the impact of ADHD beyond case counts, the researchers analyzed YLD rates—a measure of time lived with health-related disability—using standardized estimates with 95% uncertainty intervals, and compared five Asian regions over time. The results showed marked regional heterogeneity rather than a uniform Asia-wide pattern. East Asia carried the highest regional burden and followed an upward trend, while Japan and China recorded the largest national estimates. In contrast, Southeast Asia moved in the opposite direction and declined over the study period. Across all regions, ADHD-related disability was concentrated in childhood and early adolescence, peaked at ages 10-14, and then declined progressively; this age peak was particularly pronounced in East Asia. Males consistently had higher rates than females across regions and age groups. The team also compared changes among children aged 0-14 before the pandemic (2015-2019) and during the subsequent period (2019-2023). Most countries showed increases, with the Republic of Korea shifting from a decline to a marked rise, although these patterns cannot establish that the pandemic caused the increase. Finally, higher SDI was associated with higher estimated ADHD disability, a relationship that may partly reflect differences in recognition and access to diagnosis rather than underlying disease alone. These regional contrasts indicate that Asia-wide averages can obscure important national differences and should be interpreted alongside local diagnostic and service contexts.

The authors said the central message is not simply that some countries have higher ADHD estimates than others, but that the burden follows recognizable patterns that can inform support. They said the concentration of disability in early adolescence makes timely recognition especially important, while the consistently higher estimates among males should not obscure girls whose symptoms may be less readily noticed. The authors also emphasized that differences between countries require careful interpretation: better detection, health service access, and reporting can influence estimated burden. Pandemic-era increases, they explained, should be understood as observed trends rather than proof of a single cause.

These findings have practical implications for schools, clinicians, and policymakers. Schools can train teachers to recognize diverse ADHD presentations—including less obvious inattentive symptoms in girls—and strengthen referral pathways, classroom management, and social-emotional learning, especially around ages 10-14. Clinicians can prioritize early assessment in this age group, attend to sex-specific symptom profiles, integrate screening into primary care, and link families to evidence-based behavioral support. Policymakers can use these regional patterns to target resources, emphasize early identification and timely treatment, and expand school- and primary-care-based services where specialist capacity is limited. Because estimates are modeled and shaped by diagnostic and reporting differences, they should guide planning and monitoring rather than rank health systems.